CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH This trial including more than 6,500 patients randomized to empagliflozin or placebo and followed for a median of 2 years. Progression of kidney disease or death from cardiovascular causes was monitored over the course of the trial. Those outcomes occurred in approximately 13% of patients in the empagliflozin group versus approximately 17% of patients in the placebo group.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
